$20.00
+1.8%Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
BCAX • NASDAQ
| Bicara Therapeutics Inc. Common Stock Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
ASSETS | ||||
CURRENT ASSETS | ||||
96.7M | 489.7M | 230.4M | 4.2M | |
318.1M | 0.0 | 0.0 | 0.0 | |
414.8M | 489.7M | 230.4M | 4.2M | |
0.0 | 0.0 | 533K | 758K | |
7.3M | 12.8M | 100K | 68K | |
422.1M | 502.5M | 231.1M | 5M | |
NON-CURRENT ASSETS | ||||
2M | 845K | 815K | 636K | |
0.0 | 59.2M | 0.0 | 0.0 | |
6.9M | 6.6M | 2.1M | 1.1M | |
8.9M | 66.7M | 2.9M | 1.7M | |
431M | 569.2M | 234M | 6.7M | |
LIABILITIES | ||||
CURRENT LIABILITIES | ||||
5.5M | 4.5M | 3.2M | 5.1M | |
5.5M | 4.5M | 3.2M | 5.1M | |
0.0 | 3.1M | 11.6M | 18.8M | |
1.1M | 607K | 0.0 | 0.0 | |
0.0 | 0.0 | 285K | 0.0 | |
22.3M | 9.8M | 0.0 | 0.0 | |
28.9M | 18M | 15.1M | 23.9M | |
NON-CURRENT LIABILITIES | ||||
593K | 0.0 | 0.0 | 0.0 | |
0.0 | 59.2M | 0.0 | 0.0 | |
0.0 | 0.0 | 17K | 85K | |
593K | 59.3M | 389K | 85K | |
0.0 | 131K | 657K | 0.0 | |
29.5M | 77.3M | 15.5M | 24M | |
SHAREHOLDERS' EQUITY | ||||
0.0 | 0.0 | 367.3M | 81.5M | |
0.0 | 7K | 2K | 2K | |
0.0 | 712.9M | 4.3M | 2.2M | |
0.0 | -221M | -153M | -101M | |
401.5M | 0.0 | 0.0 | 0.0 | |
401.5M | 491.9M | 218.5M | -17.3M | |
401.5M | 491.9M | 218.5M | -17.3M | |
SUMMARY | ||||
431M | 569.2M | 234M | 6.7M | |
318.1M | 0.0 | 0.0 | 0.0 | |
1.7M | 738K | 657K | 0.0 | |
-95M | -489M | -229.8M | -4.2M | |
54,563,183 | 54,563,183 | 54,563,183 | 54,563,183 |
BCAX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | April 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 30, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 06, 2025 | 2025 |
Continue your BCAX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.